{"schema_version":"secwatch.filing_event.v1","accession":"0001656423-22-000039","form_type":"8-K","ticker":"BXP","cik":"0001037540","company_name":"BXP, Inc.","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.347293+00:00","generated_at":"2026-06-23T00:39:54.902961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BXP Q3 EPS $2.29 beats mid-point by $1.54; FFO $1.91; 2023 guidance lower","bullets":["Revenue $790.5M (+8.3% YoY); net income $361M ($2.29 EPS); FFO $299.8M ($1.91).","EPS beat included $1.50 gain on sale of 601 Mass Ave ($531M gross); FFO beat by $0.04.","FY2022 EPS guidance $5.55-$5.57, FFO $7.51-$7.53; FY2023 EPS $2.27-$2.42, FFO $7.15-$7.30.","Leased 1.4M SF in Q3; acquired 125 Broadway lab in Kendall Sq for ~$592.4M; disposed 601 Mass Ave and land parcels.","Agreed to acquire ~27% interest in 200 Fifth Ave, NYC for ~$280.2M and sell Avant residential for ~$141M."],"urls":{"canonical":"https://secwatch.observer/filing/0001656423-22-000039","json":"https://secwatch.observer/filing/0001656423-22-000039.json","markdown":"https://secwatch.observer/filing/0001656423-22-000039.md","text":"https://secwatch.observer/filing/0001656423-22-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1037540/000165642322000039/0001656423-22-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1037540/000165642322000039/bxp-20221025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:39:54.902961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}